All In Biotech

Drug Trial Radar · NCT07150806

RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma

Progressive/Recurrent Intracranial Meningioma Treated With SSTR-Targeted Alpha Emitter RYZ101 (PRIMe-STAR)

Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Nov 12, 2025

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Joshua PalmerAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
RayzeBio, Inc.
First posted
Sep 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I/II tests the safety, side effects, best dose and how well giving RYZ101 works for the treatment of patients with intracranial meningioma that is growing, spreading, or getting worse (progressive) or that has come back after a period of improvement (recurrent). RYZ101 is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177-dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving RYZ101 may be safe, tolerable and/or effective in treating patients with progressive or recurrent intracranial meningioma.

Conditions

  • Recurrent Meningioma

Interventions

  • Actinium Ac 225 DOTATATE RYZ101Drug

    Given IV

  • Biospecimen CollectionProcedure

    Undergo blood and urine sample collection

  • Computed TomographyProcedure

    Undergo CT scan

  • Echocardiography TestProcedure

    Undergo echocardiography

  • Gallium Ga 68-DOTATATERadiation

    Given IV

  • L-lysine/L-arginine-containing Amino AcidDrug

    Given IV

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • Multigated Acquisition ScanProcedure

    Undergo MUGA scan

  • Positron Emission TomographyProcedure

    Undergo PET scan

  • Somatostatin Receptor Positron Emission TomographyProcedure

    Undergo SSTR PET scan

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS)Time frame: At 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.